Antibiotic intermediates (6-APA, 7-ACA): Production
How India restarted penicillin making after two decades
What this tab covers Who makes it and how much: world capacity and output, utilisation, the top producing countries and companies globally and in India, concentration, new capacity coming, and each region's position.| Measure | Figure | Detail | Source |
|---|---|---|---|
| World capacity | not published globally; India penicillin G 15,000 t/yr (Lyfius, 2024) | Aurobindo (2024) | |
| World output | not published | ||
| Capacity utilisation | not published | Lyfius began production in FY 2024-25 and applied for anti-dumping protection in 2026, citing material retardation of a new industry. | Open Magazine (Oct 2026) |
| Concentration | a handful of Chinese groups dominate | 6-APA makers listed in market research include Kelun, Sinopharm Weiqida, United Laboratories, Sandoz, DSM Sinochem (now Centrient) and Carbontree (Gelonghui, 2025). Shares not published. | Gelonghui (2025) |
| New capacity | PLI fermentation category: penicillin G, 7-ACA, erythromycin thiocyanate, clavulanic acid | Commissioned: Lyfius penicillin G (2024), Kinvan clavulanic acid. 7-ACA and erythromycin thiocyanate projects not confirmed as commissioned. | Department of Pharmaceuticals PLI guidelines (2020); PSU Watch (2026) |
Top producing countries
- China: dominant in penicillin G, 6-APA and 7-ACA; 87% of India's antibiotic imports
- India: penicillin G 15,000 t/yr since 2024; clavulanic acid 400 t/yr
- European Union: Sandoz Kundl (Austria) integrated penicillin; 6-APA exports covered by India's 2026 probe
Largest producers: global
| Company | Country | Volume | Year | Source |
|---|---|---|---|---|
| United Laboratories volumes not published | China | not published | 2025 | Gelonghui |
| Kelun Industry Group | China | not published | 2025 | Gelonghui |
| Sinopharm Weiqida | China | not published | 2025 | Gelonghui |
| Sandoz last large Western integrated penicillin site (indicative) | Switzerland / Austria | not published | 2025 | Gelonghui |
| Centrient Pharmaceuticals supports Indian amoxicillin probe | Netherlands | not published | 2026 | Open Magazine |
Largest producers: India
| Company | Country | Volume | Year | Source |
|---|---|---|---|---|
| Lyfius Pharma (Aurobindo) Kakinada SEZ, Andhra Pradesh | India | 15,000 t/yr penicillin G | 2024 | PSU Watch (2026) |
| Apitoria Pharma (Aurobindo) anti-dumping applicant | India | not published | 2026 | Open Magazine |
| Qule Pharma anti-dumping applicant | India | not published | 2026 | Open Magazine |
| Kinvan (DPB group) Rs 505 crore investment | India | 400 t/yr clavulanic acid | 2026 | PSU Watch (2026) |
| Virchow Petrochemicals also imports | India | not published | 2026 | World Trade Scanner on DGTR |
India stopped making penicillin G in the 2000s when Chinese prices fell (indicative) and restarted only with the Lyfius PLI plant in 2024. 7-ACA remains imported.
Position by region
| Region | Position |
|---|---|
| US | Imports nearly all amoxicillin API and 6-APA via China and India. |
| EU | Supports Sandoz Kundl as a strategic penicillin site. |
| India | Largest new capacity; protection via MIP and probes. |
| China | Dominant supplier with pricing power. |
| Japan | Funding domestic beta-lactam API capacity after 2019 cefazolin shortage (indicative). |
| Middle East | Not material. |